Toronto, Canada --- TheNewswire — September 30, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF), a leading provider of innovative cardiac diagnostic solutions, is pleased to announce the U.S.-based Ollie Hinkle Heart Foundation will highlight Ventripoint's AI-powered heart imaging technology at the opening session of the Take Heart Conference: Turning Limitations Into Possibilities.

"We have selected a handful of breakthrough technologies to advance heart care for children, adults, and the families who support them,” said Beth Rumack, RN, MSN, MBA, NNP-BC, Chief Operating Officer of the Ollie Hinkle Heart Foundation. “Ventripoint is a technology we believe many hospitals worldwide can trust and benefit from because it can often substitute for MRI scans, which are costly, often unavailable due to long waiting lists or geography, and not always suitable for children or pregnant women."

Ventripoint is rapidly emerging as a trusted technology for delivering vital diagnostic images of all four chambers of the heart. By utilizing advanced AI algorithms, it transforms standard ultrasound images into detailed 3D scans, offering a cost-effective and accessible alternative to expensive and often unavailable MRI scans. Already in use at leading hospitals across the United States, Canada, the United Kingdom, and Europe, Ventripoint's technology is revolutionizing cardiac care by providing clinicians with critical diagnostic information quickly and efficiently, at a fraction of the time and cost of cardiac MRIs.

Dr. Brian Soriano, MD, FASE, Cardiologist will present on Ventripoint’s technology during the conference, on Oct. 4. His presentation will focus on how Ventripoint’s innovation is transforming heart imaging for children and patients of all ages in his practice.

"We are honored to be recognized by Take Heart and the Ollie Hinkle Heart Foundation,” said Hugh MacNaught, CEO of Ventripoint. “Ventripoint's AI-powered heart imaging technology is a new advancement in pediatric and adult healthcare. By providing accurate and comprehensive heart diagnostics using ultrasound and AI, we are already improving accessibility and patient outcomes in the United States, Canada, the UK and Europe."

Conference details:

The Take Heart Conference: Turning Limitations Into Possibilities  

October 4-5, 2024 | 12pm-3pm CST & 10am-1pm CST

Registration: https://theohhf.org/take-heart-conference/

For Further Information Please Contact

Hugh MacNaught

President and CEO

This email address is being protected from spambots. You need JavaScript enabled to view it. 

(604) 671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.